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Abstract: 
Objectives:  Suppressive HSV therapy can decrease plasma, cervical, and rectal HIV-1 
levels in HSV-2/HIV-1 co-infected persons.  We evaluated the effect of HSV-2 
suppression on seminal HIV-1 levels.   
Design:  Twenty antiretroviral therapy (ART)–naive HIV-1/HSV-2–MSM in Lima, Peru, 
with CD4 cell counts >200 cells/µL randomly received valacyclovir 500 mg twice daily 
or placebo for 8 weeks, then the alternative regimen for 8 weeks after a 2 week washout.  
Peripheral blood and semen specimens were collected weekly. Anogenital swab 
specimens for HSV DNA were self-collected daily and during clinic visits.   
Methods: HIV-1 RNA was quantified in seminal and blood plasma by TaqMan real-time 
polymerase chain reaction (rt-PCR) or Roche Amplicor Monitor assays.  HSV and 
seminal cytomegalovirus (CMV) were quantified by rt-PCR. Linear mixed models 
examined differences within subjects by treatment arm. 
Results: Median CD4 count of participants was 424 cells/µL.  HIV-1 was detected in 
71% of 231 semen specimens.  HSV was detected from 29% and 4.4% of swabs on 
placebo and valacyclovir, respectively (P<0.001). Valacyclovir significantly reduced the 
proportion of days with detectable seminal HIV-1 (63% during valacyclovir vs. 78% 
during placebo, p=0.04).  The quantity of HIV-1 in semen was 0.25 log10 copies/mL 
lower (95%CI -0.40 to -0.10, p=0.001) during the valacyclovir arm compared with 
placebo, a 44% reduction.  CD4 count (p=0.32) and seminal cellular CMV quantity 
(p=0.68) did not predict seminal plasma HIV-1 level. 
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Conclusions:  Suppressive valacyclovir reduced seminal HIV-1 levels in HIV-1/HSV-2 
co-infected MSM not receiving ART. The significance of this finding will be evaluated in 
a trial with HIV-1 transmission as the outcome. 
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INTRODUCTION 
The earliest reports of interactions between HSV-2 and HIV-1 infections were from the 
1980s, including among men who have sex with men (MSM)1.  Recently, several studies 
have shown that daily suppressive antiviral therapy for HSV reduces plasma, cervical and 
rectal HIV-1 levels in HIV-1 and HSV-2 infected adults2-5;  a clinical trial to assess the 
efficacy of this approach for reduction of sexual transmission of HIV-1 is ongoing6.  
Plasma HIV-1 level has been demonstrated to be a significant biologic marker of HIV-1 
transmission risk from an HIV-infected partner7, 8.  Semen is the main biologic fluid for 
exposure from HIV-infected men to their female and male partners during insertive sex9.  
However, a direct relationship between seminal HIV-1 level and transmission has not 
been shown in part due to difficulties in conducting sufficiently large, prospective studies 
of HIV-1 discordant couples with collection of blood and genital samples7.   
 
HIV-1 transmission is related to many factors10, and reductions in plasma and seminal 
HIV-1 levels may lead to reduced HIV-1 infectiousness.  Although prior studies have 
demonstrated that HSV suppression reduces plasma, cervical and rectal HIV-1 levels, no 
studies have assessed the effect of HSV suppression on seminal HIV-1 levels. We 
evaluated seminal HIV-1 levels in a randomized double-blind, placebo-controlled 
crossover trial among HIV-1/HSV-2 coinfected MSM that demonstrated a mean 0.33 
log10 reduction in plasma HIV-1 during twice daily suppressive valacyclovir3. 
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METHODS 
Study Characteristics 
Study design. As previously described3, a randomized, double-blind, placebo-controlled 
crossover trial of valacyclovir for HSV and HIV-1 suppression was conducted in Lima, 
Peru.  Briefly, participants were MSM who were >18 years old, were seropositive for 
HIV-1 and HSV-2, had no history of antiretroviral use, and had a CD4 cell count >200 
cells/µL per Peruvian guidelines for ART initiation at the time of study implementation3. 
Exclusion criteria included current or planned therapy with antiretrovirals or antivirals for 
HSV (acyclovir, famciclovir, or valacyclovir), a history of adverse reactions to these 
antivirals, a history of seizures, a serum creatinine level >2.0 mg/dL, or  hematocrit 
<30%.   
 
The human experimentation guidelines of the US Department of Health and Human 
Services and the individual institutions were followed in the conduct of the clinical 
research. The institutional review boards of the University of Washington and 
the Asociación Civil Impacta Salud y Educación approved the protocol.   
 
Study medication. Valacyclovir (500 mg orally twice daily) and matching placebo were 
supplied by GlaxoSmithKline. As previously described3, subjects were randomly 
assigned 1:1 (valacyclovir to placebo) in blocks of 10. After 8 weeks of the initial 
treatment, each participant crossed over to the alternative treatment for 8 weeks, 
separated by a 2-week washout period with daily placebo. Open-label valacyclovir (1 g 
orally twice daily for 3 days) was dispensed for symptomatic herpes recurrences.  Four 
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men were treated with open-label valacyclovir for genital herpes recurrences during the 
study, of which 3 occurred during placebo administration. 
 
Study procedures. At enrollment, participants underwent a physical exam, and had blood, 
semen and HSV swabs collected. Participants came to clinic 3 times a week.  In addition 
to anoscopy samples for HIV-1 and HSV, and blood draws reported previously, weekly 
semen samples were collected into sterile containers by study participants either just prior 
to the clinic visit or in a private room at the clinic.  Seminal plasma was used for HIV-1 
analysis and the cell component was used for CMV analysis.  Participants also collected 
daily swabs of genital and perianal skin at home for HSV DNA PCR, as described3.   
 
Specimen Collection and Laboratory Procedures 
Blood specimens. Peripheral blood was collected into tubes containing EDTA (Becton 
Dickinson) and separated within 6 h into plasma and mononuclear cells by ficoll-hypaque 
gradient centrifugation. Lymphocyte subsets were determined by flow cytometry 
methods in Lima.  Plasma aliquots were frozen at -70° C and transported to the 
University of Washington Retrovirology Laboratory. Blood plasma preparation methods 
have been described previously3 
 
Semen specimens.  Within 6 hours of collection, vials containing whole semen 
specimens were frozen at -80° C.  Semen samples were transported to the University of 
Washington on dry ice and stored at -80 °C until tested.  Vials were thawed and 
microcentrifuged at 16,000g for 15 minutes to separate seminal plasma and cell 
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components.  Seminal plasma aliquots (250 µL) were diluted 1:5 with RPMI media11 and 
centrifuged for 1 h at 23,000g.  The pellets were resuspended in bioMerieux lysis buffer 
and extracted using the MiniMAG® Extraction system, which uses magnetic silica beads 
based on the Boom® Technology (bioMerieux, Durham, NC).   
 
HIV-1 RNA quantitation assays.  HIV-1 RNA was quantified using an independently 
validated TaqMan real-time RNA PCR (rt-PCR) amplification assay or the Amplicor 
HIV Monitor assay (Roche Molecular Systems)3, 12.  For the TaqMan assay, the lower 
limit of detection (LLOD) for HIV-1 quantitation in blood plasma was 120 (2.1 log10) 
HIV-1 RNA copies/mL; for the Amplicor HIV Monitor assay, the LLOD in plasma was 
400 (2.6 log10) HIV-1 RNA copies/mL. In semen, LLOD were 300 and 800 copies/mL 
for the Taqman real-time PCR or Roche Amplicor® Monitor, respectively.   
 
HSV and CMV DNA Assays 
DNA was extracted from each specimen. A fluorescent probe– based rt-PCR (TaqMan; 
Applied Biosystems) assay was used to quantitate HSV3, 13 and CMV levels14.  LLOD for 
HSV detection was 2.69 log10 copies/mL and for CMV detection was 10 copies/mL. 
 
Statistical Methods 
HSV shedding rate was computed by dividing the days with detectable HSV in swabs 
collected at home or in the clinic by the total days of swab collection. All analyses were 
done on an intent-to-treat basis, excluding the first day of study drug administration from 
each arm. Laboratory testing was performed without knowledge of treatment assignment. 
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For undetectable HIV-1 values, the midpoint between zero and the LLOD was used15; 
quantitative HIV-1 and CMV values were log-transformed.  HSV shedding was 
examined as a binary variable (detected vs. not detected), as HSV DNA was detected in 
only a small proportion of samples. Since CMV detection was more common, quantity 
detected was retained and a sensitivity analysis was performed to examine the influence 
of the values assigned to amounts below the limit of detection.  There was no difference 
in the outcomes between analyses done with undetectable CMV set to zero vs. when 
undetectable quantities were set to a random value between 0 and the lower limit of 
detection. 
 
Linear mixed models were used to examine quantitative differences within subjects by 
treatment arm, using multivariate models to evaluate the effects of co-factors. Because 
HIV-1 quantity was modeled on the log10 scale, coefficients from models are 
exponentiated and compared with 1 to compute percent change in HIV-1 quantity. 
Statistical analysis was performed using SAS for Windows (version 9.1).   
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RESULTS:  
The study population has been described previously3, with one subject excluded due to 
persistent semen assay inhibition, so the analysis included 19 men.  The median age was 
39 years [range 22-45] and median CD4 count was 424 cells/μL [range 232-869].  Using 
adherence data from pill counts conducted every two weeks, participants took a median 
of 97% [range: 65.8-100%] of pills.  
 
HSV and HIV-1 detection and levels 
Overall, HIV-1 was detected at least once in semen samples from all 19 participants and 
in 71% of 231 semen specimens (Table 1).  HSV was detected in 29% and 4.4% of rectal 
and anogenital swab specimens from participants on placebo and valacyclovir, 
respectively (P<0.001).  
 
Daily valacyclovir suppression reduced the proportion of seminal samples with detectable 
HIV-1 (63% of samples during valacyclovir vs. 78% during placebo, p=0.04, Table 1) 
and the quantity of HIV-1 in seminal plasma (Figure 1).  Mean seminal HIV-1 level 
(log10 copies/mL) was 3.19 during valacyclovir and 3.48 during placebo treatment.   
 
In a linear mixed model, the quantity of HIV-1 in semen was 0.25 log10 lower (95%CI -
0.40 to -0.10, p=0.001) during the valacyclovir arm compared with placebo, a 44% 
reduction.  The mean seminal HIV-1 level was reduced in 15 participants and increased 
in 4 participants during valacyclovir therapy.   
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Effect of covariates on seminal HIV-1 levels 
There was a trend towards an association between plasma HIV-1 RNA and seminal HIV-
1 levels (p=0.07), but the addition of plasma HIV-1 RNA levels to the model minimally 
changed the effect of valacyclovir on seminal HIV-1 levels (0.29 log10 decrease in 
seminal HIV-1 with valacyclovir; 95%CI -0.48 to -0.11, p=0.002).  CD4 cell count did 
not predict seminal HIV-1 levels (p=0.32).  CMV was detected in 111 of 208 tested 
semen samples and in at least one sample from 11of 18 men, and was not quantitatively 
associated with seminal HIV-1 levels (p=0.68) or administration of valacyclovir (p=0.68; 
mean CMV level=2.3 log10 on placebo and 2.1 log10 on valacyclovir).  
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DISCUSSION: 
Our study is the first to demonstrate that suppressive valacyclovir reduced seminal HIV-1 
levels in HIV-1/HSV-2 co-infected MSM with intermediate CD4 counts not receiving 
ART.  A 0.25 log10 reduction in HIV-1 levels in semen was observed during multiple 
time points in each study arm.  HSV-2 suppression studies have shown 0.3-0.5 log10 
reductions in plasma HIV-1 levels, and approximately 0.3 log10 reductions in HIV-1 
levels in cervical and rectal secretions2-5.  Seminal HIV-1 levels may be an important 
surrogate for HIV-1 infectiousness and co-factors, such as HSV-2 reactivation, likely 
influence HIV-1 infectiousness10.  
  
Inclusion of plasma HIV-1 in the linear effects model did not meaningfully alter 
valacyclovir’s effect on HIV-1 shedding.  This finding suggests that the association may 
not be strongly linked to plasma HIV-1 level and that the male genital tract could be a 
distinct virologic compartment from the blood16.  An indirect mechanism of HSV-2 
suppression on reduction of seminal HIV-1 levels appears most likely as HSV is rarely 
detected in semen17.  This mechanism requires further clarification.   The dose of 
valacyclovir used in this study for HSV-2 suppression is significantly lower than the 
IC50 for CMV, so we did not anticipate that valacyclovir would suppress CMV.  
However, given a previous report which indicated that seminal HIV-1 levels were 
associated with concomitant CMV shedding18, we assessed CMV reactivation as a 
covariate for seminal HIV-1 and did not find an association.  
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Our study was limited by the fact that we sampled only cell-free seminal plasma for HIV-
1 and cell associated HIV-1 may also be important in HIV-1 transmission.  Additionally, 
we examined only cell-associated CMV as a covariate due to small volumes of seminal 
samples.    
 
Recently, Butler et al. evaluated factors associated with HIV-1 transmission events in 
MSM, including seminal HIV-1 level7.  In that study of 47 men, plasma HIV-1 level and 
HSV-2 seropositivity of the source partner were the strongest predictors of HIV-1 
transmission with seminal HIV-1 level being less significant.  We have shown here that 
HSV suppression with the anti-herpes medication, valacyclovir, reduces seminal and 
plasma HIV-1 levels, which may reduce HIV-1 infectiousness.   Our findings support the 
ongoing clinical trial, Partners in Prevention, which is evaluating the effect of HSV-2 
suppression on HIV-1 transmission in HIV-1/HSV-2 co-infected men and women.  
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Table 1: Rates of HSV and HIV-1 detection and mean HIV-1 quantities for plasma and 
semen samples, by treatment arm 
 
 Both arms Placebo Valacyclovir p-value† 
HSV detection rate (anogenital 
or rectal sample) 
338/2043 
(17%) 
293/1015 
(29%) 
45/1028  
(4.4%) 
<0.001 
Seminal HIV-1 detection rate  163/231 
(71%) 
89/114 
(78%) 
74/117 
 (63%) 
0.04 
Seminal HIV-1 quantity (mean, 
log10 HIV RNA copies/ml) 
3.33 3.48 3.19 0.02 
Plasma HIV-1 detection rate 269/273 
(99%) 
135/137 
(99%) 
134/136  
(99%) 
 
Plasma HIV-1 quantity (mean, 
log10 HIV RNA copies/ml) 
4.34  4. 52 4.17 <0.001 
† p-value represents comparison between valacyclovir and placebo 
Undetectable HIV-1 levels were set halfway between zero and the lower limit of 
detection (LLOD). 
21 
Figure 1: Graph showing the percent of semen samples in each treatment arm stratified 
by seminal HIV RNA level in a randomized, double-blind placebo-controlled crossover 
trial in 19 men. Valacyclovir treatment is associated with lower detection rate and lower 
seminal HIV-1 levels.   Each bar represents the percent of samples in each treatment arm 
stratified by seminal HIV-1 level (placebo, N=113 samples.; and valacyclovir, 
N=117samples).   
 
 
 
Figure Legend: 
Undetectable HIV-1 levels were set halfway between zero and the lower limit of 
detection (LLOD), hence some values are below the LLOD for our assays. 
 
 
 
 
 
 
 
